Eureka Therapeutics Advances ARYA-3 Clinical Trial to Phase II for Liver Cancer Treatment Utilizing GPC3-Targeting ARTEMIS® T-cell Therapy
Tuesday, March 19, 2024
Eureka Therapeutics, Inc., a leading biotechnology company specializing in T-cell therapies for cancer, has announced a significant milestone with its ARYA-3 clinical trial advancing to Phase II (NCT04864054). This progression represents one of the initial engineered T-cell programs targeting solid tumors to reach this stage.
The ARYA-3 trial focuses on evaluating Eureka’s investigational ARTEMIS® ECT204 T-cell therapy in adults diagnosed with GPC3-positive advanced hepatocellular carcinoma (HCC), the primary type of liver cancer. GPC3, or Glypican 3, is a promising target for HCC treatments, present in over 70% of HCC cells. Notably, GPC3 is also found in other solid tumors like ovarian and lung cancer.
Having successfully completed Phase I, the ARYA-3 trial is currently enrolling patients for Phase II. This phase aims to provide crucial insights into the treatment's efficacy and safety in a larger patient population.
Dr. Cheng Liu, President and CEO of Eureka Therapeutics, expressed excitement about the positive safety profile and promising early efficacy signals observed in Phase I. He emphasized the significance of advancing to Phase II in their mission to develop innovative cancer therapies. Dr. Liu reiterated the company's commitment to expanding a pipeline of next-generation T-cell therapies for solid tumors.
ARYA-3 is an Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy. The approach involves collecting a patient's T cells and genetically modifying them to express Eureka’s proprietary anti-GPC3 ARTEMIS T cell receptors (AbTCR). These modified T cells are then reintroduced into the patient to specifically target and eliminate GPC3-expressing cancer cells. Eureka has previously demonstrated the advantages of its proprietary ARTEMIS T-cell receptor platform over conventional chimeric antigen receptors (CARs), including enhanced tumor infiltration, safety, and T cell persistence. The clinical trial is actively enrolling patients at both City of Hope and Kansas University Medical Center.
Source: businesswire.com
